Astrazeneca (AZN) Receivables (2009 - 2026)

Astrazeneca's Receivables history runs 18 years deep, the most recent figure standing at $14.1 billion for Q1 2026.

• In Q1 2026, Receivables rose 6.46% year-over-year to $14.1 billion; the TTM figure through Mar 2026 stood at $14.1 billion (up 6.46% YoY), while the FY2025 annual figure was $17.2 billion, up 18.16% from the prior year.
• Receivables was $14.1 billion for Q1 2026 at Astrazeneca, down from $17.2 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $17.2 billion in Q4 2025 to a low of $8.7 billion in Q1 2022.
• Historically, Receivables has averaged $12.0 billion across 5 years, with a median of $11.3 billion in 2023.
• Biggest YoY gain for Receivables was 74.97% in 2022; the steepest drop was 22.54% in 2022.
• A 5-year view of Receivables shows it stood at $8.9 billion in 2022, then soared by 55.17% to $13.8 billion in 2023, then gained by 5.71% to $14.6 billion in 2024, then increased by 18.16% to $17.2 billion in 2025, then retreated by 17.96% to $14.1 billion in 2026.
• The last three Receivables figures came in at $14.1 billion (Q1 2026), $17.2 billion (Q4 2025), and $14.3 billion (Q3 2025), per Business Quant data.